{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:28:39Z","timestamp":1773203319514,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The standard of care for fit, newly diagnosed multiple myeloma patients includes induction therapy followed by consolidative high\u2010dose chemotherapy with melphalan and autologous stem cell transplant (AHSCT). Intensified preparative regimens, such as busulfan and melphalan (BuMel), have shown promise to lengthen progression\u2010free survival (PFS). We previously reported that the addition of bortezomib to BuMel improved PFS compared to melphalan alone in CIBMTR\u2010matched controls. We now integrate the second\u2010generation protease inhibitor, carfilzomib, before and after BuMel (BuMelCar) in a phase I\/II trial with carfilzomib. Patients with NDMM, relapsed\/refractory MM (RRMM) and those failing prior AHSCT were eligible. Primary end\u2010points were safety and tolerability. Secondary end\u2010points included minimal residual disease negativity rates, PFS and OS. The study enrolled 19 patients. 73% were high risk either due to R\u2010ISS III status, adverse genetics or relapsed after prior AHSCT. The maximum tolerated dose (MTD) of carfilzomib was determined to be 36\u2009mg\/m<jats:sup>2<\/jats:sup>. Noted grade 3 toxicities were febrile neutropenia (79%), mucositis (21%) and diarrhoea (16%). The 2\u2010year PFS for the whole cohort and MTD was 89% and 100% respectively. 80% of all patients and 82% of patients in the MTD cohort achieved MRD negativity. Further studies regarding this regimen are planned.<\/jats:p>","DOI":"10.1111\/bjh.19281","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T23:25:01Z","timestamp":1704410701000},"page":"1422-1428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Busulfan, melphalan and carfilzomib high\u2010dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3428-1667","authenticated-orcid":false,"given":"Patrick","family":"Hagen","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Cardinal Bernardin Cancer Center Loyola University Chicago Stritch School of Medicine  Maywood Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-6270","authenticated-orcid":false,"given":"Joseph","family":"Norton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Cardinal Bernardin Cancer Center Loyola University Chicago Stritch School of Medicine  Maywood Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Cardinal Bernardin Cancer Center Loyola University Chicago Stritch School of Medicine  Maywood Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Campo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Cardinal Bernardin Cancer Center Loyola University Chicago Stritch School of Medicine  Maywood Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Cardinal Bernardin Cancer Center Loyola University Chicago Stritch School of Medicine  Maywood Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayeromi","family":"Gomez","sequence":"additional","affiliation":[{"name":"Clinical Research Office, Center for Translational Research and Education Loyola University Chicago  Maywood Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Stiff","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Cardinal Bernardin Cancer Center Loyola University Chicago Stritch School of Medicine  Maywood Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00693\u20103"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.08.002"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935\u2010021\u201002313\u2010z"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.022"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.959949"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(19)30023\u20107"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211012985"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010019\u201003663\u20105"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1783448"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811275"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201004\u2010017780"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.257"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102002\u201006\u20101768"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201010\u20101662"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014635"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.021"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30613\u20107"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(15)00464\u20107"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S62512"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.01.036"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.102"},{"key":"e_1_2_9_26_1","unstructured":"Carflizomib [package insert].Thousand Oaks CA:Amgen Inc;2012https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202714s025lbl.pdf"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.08.037"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201006\u2010858613"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572\u20100241.2005.00309_7.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705471"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.01.076"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:35:09Z","timestamp":1712763309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/bjh.19281"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19281","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"2023-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}